Overall, in patients who had completed therapy for breast cancer, pregnancy seems safe, with few adverse outcomes or links to shortened disease-free survival.
Reports have been limited regarding the success and safety of later pregnancy in carriers of BRCA1/2 mutations who developed breast cancer and completed therapy. Now, researchers in a consortium of 78 centers around the world have collaborated to identify patients aged 40 years or younger who had completed breast cancer treatment and who had germline pathogenic BRCA1 or BRCA2 mutations or both.
This retrospective cohort study identified 4732 eligible patients over a 20-year period with a median follow-up of 7.8 years (median patient age, 35; interquartile range, 31–38). Patients who got pregnant, compared with those who did not, were significantly more likely to be younger at cancer diagnosis, to have node-negative and hormone receptor (HR)–…
Reviewing Author
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)
DisclosuresConsultant/Advisory BoardLilly; AstraZeneca; Gilead
Grant/Research SupportBreast Cancer Research Foundation
Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment
Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)